<DOC>
	<DOCNO>NCT00163345</DOCNO>
	<brief_summary>The aim study evaluate involvement small airway asthma , determine bronchial challenge , CT-scanning , cellular marker inflammation . Ciclesonide inhale one dose level daily . The study duration consist baseline period ( 2 3 week ) treatment period ( 5 6 week ) . The study provide data safety tolerability ciclesonide .</brief_summary>
	<brief_title>Efficacy Ciclesonide Small Airways Patients With Stable Asthma ( 18 60 ) ( BY9010/M1-131 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Main Written inform consent History bronchial asthma FEV1 equal 60 % predict Stable asthma Patients good health exception asthma Main Concomitant severe disease , disease expect interfere outcome study , disease contraindication use ICS COPD ( i.e . chronic bronchitis emphysema ) and/or relevant lung disease cause alternate impairment lung function Use ICS 4 week entry baseline period Pregnancy Intention become pregnant course study Breast feeding Lack safe contraception Use drug allow Current smoker exsmokers equal 10 packyears</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Ciclesonide</keyword>
	<keyword>Small Airways</keyword>
</DOC>